Novel approaches to target pancreatic cancer

Current Cancer Drug Targets

Volumn 11, Issue 6, 2011, Pages 698-713

  Porzner, M ^a   Seufferlein, T ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Epidermal growth factor receptor inhibitor; Farnesyl transferase inhibitor; Mammalian target of rapamycin; Matrix metalloproteinase inhibitor; Notch; Pancreatic cancer; Sonic hedgehog; Targeted therapy; Vascular endothelial growth factor inhibitor

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CONATUMUMAB; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FLUOROPYRIMIDINE; FLUOROURACIL; GANITUMAB; GEMCITABINE; GI 4000; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; MARIMASTAT; MK 0752; NOTCH RECEPTOR; OXALIPLATIN; PACLITAXEL; RAPAMYCIN; SONIC HEDGEHOG PROTEIN; SORAFENIB; TANOMASTAT; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISMODEGIB;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GENETIC TRAIT; HEART DISEASE; HUMAN; HYPERTENSION; INFECTION; INTESTINE PERFORATION; LOW DRUG DOSE; METASTASIS; MOLECULARLY TARGETED THERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERFORATION; PROTEINURIA; RISK FACTOR; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TUMOR; TUMOR HOST INTERACTION; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959933116     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911796191079     Document Type: Article

References (66)

1. Hemminki, K.; Li, X.; Sundquist, J.; Sundquist, K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist 2010, 15 (6), 548-555.
2. Rozenblum, E.; Schutte, M.; Goggins, M.; Hahn, S. A.; Panzer, S.; Zahurak, M.; Goodman, S. N.; Sohn, T. A.; Hruban, R. H.; Yeo, C. J.; Kern, S. E. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997, 57 (9), 1731-1734.
3. Jones, S.; Zhang, X.; Parsons, D. W.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S. M.; Fu, B.; Lin, M. T.; Calhoun, E. S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D. R.; Hidalgo, M.; Leach, S. D.; Klein, A. P.; Jaffee, E. M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman, J. R.; Kern, S. E.; Hruban, R. H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321 (5897), 1801-1806.
4. Bachem, M. G.; Schunemann, M.; Ramadani, M.; Siech, M.; Beger, H.; Buck, A.; Zhou, S.; Schmid-Kotsas, A.; Adler, G. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005, 128 (4), 907-921.
5. Bachem, M. G.; Zhou, S.; Buck, K.; Schneiderhan, W.; Siech, M. Pancreatic stellate cells--role in pancreas cancer. Langenbecks Arch. Surg. 2008, 393 (6), 891-900.
6. Bramhall, S. R.; Allum, W. H.; Jones, A. G.; Allwood, A.; Cummins, C.; Neoptolemos, J. P. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br. J. Surg. 1995, 82 (1), 111-115.
7. Li, D.; Xie, K.; Wolff, R.; Abbruzzese, J. L. Pancreatic cancer. Lancet 2004, 363 (9414), 1049-1057.
8. Bramhall, S. R.; Rosemurgy, A.; Brown, P. D.; Bowry, C.; Buckels, J. A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 2001, 19 (15), 3447-3455.
9. Bramhall, S. R.; Schulz, J.; Nemunaitis, J.; Brown, P. D.; Baillet, M.; Buckels, J. A. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 2002, 87 (2), 161-167.
10. Moore, M. J.; Hamm, J.; Dancey, J.; Eisenberg, P. D.; Dagenais, M.; Fields, A.; Hagan, K.; Greenberg, B.; Colwell, B.; Zee, B.; Tu, D.; Ottaway, J.; Humphrey, R.; Seymour, L. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2003, 21 (17), 3296-3302.
11. Cohen, S. J.; Ho, L.; Ranganathan, S.; Abbruzzese, J. L.; Alpaugh, R. K.; Beard, M.; Lewis, N. L.; McLaughlin, S.; Rogatko, A.; Perez-Ruixo, J. J.; Thistle, A. M.; Verhaeghe, T.; Wang, H.; Weiner, L. M.; Wright, J. J.; Hudes, G. R.; Meropol, N. J. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 2003, 21 (7), 1301-1306.
12. Macdonald, J. S.; McCoy, S.; Whitehead, R. P.; Iqbal, S.; Wade, J. L., 3rd; Giguere, J. K.; Abbruzzese, J. L. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest. New Drugs 2005, 23 (5), 485-487.
13. Van Cutsem, E.; van de Velde, H.; Karasek, P.; Oettle, H.; Vervenne, W. L.; Szawlowski, A.; Schoffski, P.; Post, S.; Verslype, C.; Neumann, H.; Safran, H.; Humblet, Y.; Perez Ruixo, J.; Ma, Y.; Von Hoff, D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 2004, 22, (8), 1430-1438.
14. Ortega, N.; Jonca, F.; Vincent, S.; Favard, C.; Ruchoux, M. M.; Plouet, J. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype. Am. J. Pathol. 1997, 151 (5), 1215-1224.
15. Nor, J. E.; Christensen, J.; Mooney, D. J.; Polverini, P. J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 1999, 154 (2), 375-384.
16. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13 (1), 9-22.
17. Kindler, H. L.; Friberg, G.; Singh, D. A.; Locker, G.; Nattam, S.; Kozloff, M.; Taber, D. A.; Karrison, T.; Dachman, A.; Stadler, W. M.; Vokes, E. E. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2005, 23 (31), 8033-8040.
18. Ko, A. H.; Dito, E.; Schillinger, B.; Venook, A. P.; Xu, Z.; Bergsland, E. K.; Wong, D.; Scott, J.; Hwang, J.; Tempero, M. A. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest. New Drugs 2008, 26 (5), 463-471.
19. Javle, M.; Yu, J.; Garrett, C.; Pande, A.; Kuvshinoff, B.; Litwin, A.; Phelan, J., 3rd; Gibbs, J.; Iyer, R. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br. J. Cancer 2009, 100 (12), 1842-1845.
20. Kindler, H. L.; Niedzwiecki, D.; Hollis, D.; Sutherland, S.; Schrag, D.; Hurwitz, H.; Innocenti, F.; Mulcahy, M. F.; O'Reilly, E.; Wozniak, T. F.; Picus, J.; Bhargava, P.; Mayer, R. J.; Schilsky, R. L.; Goldberg, R. M. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 2010, 28 (22), 3617-3622.
21. Spano, J. P.; Chodkiewicz, C.; Maurel, J.; Wong, R.; Wasan, H.; Barone, C.; Letourneau, R.; Bajetta, E.; Pithavala, Y.; Bycott, P.; Trask, P.; Liau, K.; Ricart, A. D.; Kim, S.; Rixe, O. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008, 371 (9630), 2101-2108.
22. Olive, K. P.; Jacobetz, M. A.; Davidson, C. J.; Gopinathan, A.; McIntyre, D.; Honess, D.; Madhu, B.; Goldgraben, M. A.; Caldwell, M. E.; Allard, D.; Frese, K. K.; Denicola, G.; Feig, C.; Combs, C.; Winter, S. P.; Ireland-Zecchini, H.; Reichelt, S.; Howat, W. J.; Chang, A.; Dhara, M.; Wang, L.; Ruckert, F.; Grutzmann, R.; Pilarsky, C.; Izeradjene, K.; Hingorani, S. R.; Huang, P.; Davies, S. E.; Plunkett, W.; Egorin, M.; Hruban, R. H.; Whitebread, N.; McGovern, K.; Adams, J.; Iacobuzio-Donahue, C.; Griffiths, J.; Tuveson, D. A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324 (5933), 1457-1461.
23. Frederick, L.; Wang, X. Y.; Eley, G.; James, C. D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000, 60 (5), 1383-1387.
24. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350 (21), 2129-2139.
25. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreaticcancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25 (15), 1960-1966.
26. Ardavanis, A.; Kountourakis, P.; Karagiannis, A.; Doufexis, D.; Tzovaras, A. A.; Rigatos, G. Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer. Anticancer Res. 2009, 29 (12), 5211-5217.
27. Kulke, M. H.; Blaszkowsky, L. S.; Ryan, D. P.; Clark, J. W.; Meyerhardt, J. A.; Zhu, A. X.; Enzinger, P. C.; Kwak, E. L.; Muzikansky, A.; Lawrence, C.; Fuchs, C. S. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J. Clin. Oncol. 2007, 25 (30), 4787-4792.
28. Xiong, H. Q.; Rosenberg, A.; LoBuglio, A.; Schmidt, W.; Wolff, R. A.; Deutsch, J.; Needle, M.; Abbruzzese, J. L. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J. Clin. Oncol. 2004, 22 (13), 2610-2616.
29. Cascinu, S.; Berardi, R.; Labianca, R.; Siena, S.; Falcone, A.; Aitini, E.; Barni, S.; Di Costanzo, F.; Dapretto, E.; Tonini, G.; Pierantoni, C.; Artale, S.; Rota, S.; Floriani, I.; Scartozzi, M.; Zaniboni, A. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 2008, 9 (1), 39-44.
30. Kullmann, F.; Hollerbach, S.; Dollinger, M. M.; Harder, J.; Fuchs, M.; Messmann, H.; Trojan, J.; Gabele, E.; Hinke, A.; Hollerbach, C.; Endlicher, E. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br. J. Cancer. 2009, 100 (7), 1032-1036.
31. Philip, P. A.; Benedetti, J.; Corless, C. L.; Wong, R.; O'Reilly, E. M.; Flynn, P. J.; Rowland, K. M.; Atkins, J. N.; Mirtsching, B. C.; Rivkin, S. E.; Khorana, A. A.; Goldman, B.; Fenoglio-Preiser, C. M.; Abbruzzese, J. L.; Blanke, C. D. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Groupdirected intergroup trial S0205. J. Clin. Oncol. 2010, 28 (22), 3605-3610.
32. Van Cutsem, E.; Vervenne, W. L.; Bennouna, J.; Humblet, Y.; Gill, S.; Van Laethem, J. L.; Verslype, C.; Scheithauer, W.; Shang, A.; Cosaert, J.; Moore, M. J. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27 (13), 2231-2237.
33. Ko, A. H.; Venook, A. P.; Bergsland, E. K.; Kelley, R. K.; Korn, W. M.; Dito, E.; Schillinger, B.; Scott, J.; Hwang, J.; Tempero, M. A. A phase II study of bevacizumab plus erlotinib for gemcitabinerefractory metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 2010, 66 (6), 1051-1057.
34. Tsavaris, N.; Kosmas, C.; Skopelitis, H.; Gouveris, P.; Kopterides, P.; Loukeris, D.; Sigala, F.; Zorbala-Sypsa, A.; Felekouras, E.; Papalambros, E. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest. New Drugs. 2005, 23 (4), 369-375.
35. Thayer, S. P.; di Magliano, M. P.; Heiser, P. W.; Nielsen, C. M.; Roberts, D. J.; Lauwers, G. Y.; Qi, Y. P.; Gysin, S.; Fernandez-del Castillo, C.; Yajnik, V.; Antoniu, B.; McMahon, M.; Warshaw, A. L.; Hebrok, M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425 (6960), 851-856.
36. Morton, J. P.; Mongeau, M. E.; Klimstra, D. S.; Morris, J. P.; Lee, Y. C.; Kawaguchi, Y.; Wright, C. V.; Hebrok, M.; Lewis, B. C. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (12), 5103-5108.
37. Bailey, J. M.; Mohr, A. M.; Hollingsworth, M. A. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene 2009, 28 (40), 3513-3525.
38. Nolan-Stevaux, O.; Lau, J.; Truitt, M. L.; Chu, G. C.; Hebrok, M.; Fernandez-Zapico, M. E.; Hanahan, D. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009, 23 (1), 24-36.
39. Stanton, B. Z.; Peng, L. F. Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol. Biosyst. 2010 6, (1), 44-54.
40. Shaw, R. J.; Cantley, L. C. Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature 2006, 441 (7092), 424-430.
41. Bjornsti, M. A.; Houghton, P. J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4 (5), 335-348.
42. Hay, N.; Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 2004, 18 (16), 1926-1945.
43. Grewe, M.; Gansauge, F.; Schmid, R. M.; Adler, G.; Seufferlein, T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. 1999, 59 (15), 3581-3587.
44. Schlieman, M. G.; Fahy, B. N.; Ramsamooj, R.; Beckett, L.; Bold, R. J. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br. J. Cancer 2003, 89 (11), 2110-2115.
45. Yamamoto, S.; Tomita, Y.; Hoshida, Y.; Morooka, T.; Nagano, H.; Dono, K.; Umeshita, K.; Sakon, M.; Ishikawa, O.; Ohigashi, H.; Nakamori, S.; Monden, M.; Aozasa, K. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2004, 10 (8), 2846-2850.
46. Wolpin, B. M.; Hezel, A. F.; Abrams, T.; Blaszkowsky, L. S.; Meyerhardt, J. A.; Chan, J. A.; Enzinger, P. C.; Allen, B.; Clark, J. W.; Ryan, D. P.; Fuchs, C. S. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27 (2), 193-198.
47. Javle, M. M.; Shroff, R. T.; Xiong, H.; Varadhachary, G. A.; Fogelman, D.; Reddy, S. A.; Davis, D.; Zhang, Y.; Wolff, R. A.; Abbruzzese, J. L. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 2010, 10, 368.
48. Garrido-Laguna, I.; Tan, A. C.; Uson, M.; Angenendt, M.; Ma, W. W.; Villaroel, M. C.; Zhao, M.; Rajeshkumar, N. V.; Jimeno, A.; Donehower, R.; Iacobuzio-Donahue, C.; Barrett, M.; Rudek, M. A.; Rubio-Viqueira, B.; Laheru, D.; Hidalgo, M. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br. J. Cancer 2010, 103 (5), 649-655.
49. Radtke, F.; Raj, K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat. Rev. Cancer. 2003, 3 (10), 756-767.
50. Bray, S. J. Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell Biol. 2006, 7 (9), 678-689.
51. Roy, M.; Pear, W. S.; Aster, J. C. The multifaceted role of Notch in cancer. Curr. Opin. Genet. Dev. 2007, 17 (1), 52-59.
52. Iso, T.; Kedes, L.; Hamamori, Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J. Cell Physiol. 2003, 194 (3), 237-255.
53. Kageyama, R.; Ohtsuka, T.; Kobayashi, T. The Hes gene family: repressors and oscillators that orchestrate embryogenesis. Development 2007, 134 (7), 1243-1251.
54. Miyamoto, Y.; Maitra, A.; Ghosh, B.; Zechner, U.; Argani, P.; Iacobuzio-Donahue, C. A.; Sriuranpong, V.; Iso, T.; Meszoely, I. M.; Wolfe, M. S.; Hruban, R. H.; Ball, D. W.; Schmid, R. M.; Leach, S. D. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell. 2003, 3 (6), 565-576.
55. Buchler, P.; Gazdhar, A.; Schubert, M.; Giese, N.; Reber, H. A.; Hines, O. J.; Giese, T.; Ceyhan, G. O.; Muller, M.; Buchler, M. W.; Friess, H. The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg. 2005, 242 (6), 791-800, discussion 800-791.
56. Sawey, E. T.; Johnson, J. A.; Crawford, H. C. Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (49), 19327-19332.
57. Plentz, R.; Park, J. S.; Rhim, A. D.; Abravanel, D.; Hezel, A. F.; Sharma, S. V.; Gurumurthy, S.; Deshpande, V.; Kenific, C.; Settleman, J.; Majumder, P. K.; Stanger, B. Z.; Bardeesy, N. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009, 136 (5), 1741-1749 e1746.
58. Evans, J. D.; Stark, A.; Johnson, C. D.; Daniel, F.; Carmichael, J.; Buckels, J.; Imrie, C. W.; Brown, P.; Neoptolemos, J. P. A phase II trial of marimastat in advanced pancreatic cancer. Br. J. Cancer. 2001, 85 (12), 1865-1870.
59. Crane, C. H.; Winter, K.; Regine, W. F.; Safran, H.; Rich, T. A.; Curran, W.; Wolff, R. A.; Willett, C. G. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J. Clin. Oncol. 2009, 27 (25), 4096-4102.
60. Small, W., Jr.; Mulcahy, M. F.; Rademaker, A.; Bentrem, D. J.; Benson, A. B.; Weitner, B. B.; Talamonti, M. S. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80 (2), 476-482.
61. Fogelman, D.; Jafari, M.; Varadhachary, G. R.; Xiong, H.; Bullock, S.; Ozer, H.; Lin, E.; Morris, J.; Cunningham, P.; Bennett, B.; Abbruzzese, J. L.; Wolff, R. A. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother. Pharmacol. 2011.
62. Okusaka, T.; Furuse, J.; Funakoshi, A.; Ioka, T.; Yamao, K.; Ohkawa, S.; Boku, N.; Komatsu, Y.; Nakamori, S.; Iguchi, H.; Ito, T.; Nakagawa, K.; Nakachi, K. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci. 2011, 102 (2), 425-431.
63. Oh, D. Y.; Lee, K. W.; Lee, K. H.; Sohn, C. H.; Park, Y. S.; Zang, D. Y.; Ryoo, H. M.; Song, H. S.; Kim, J. S.; Kang, H. J.; Kim, B. S.; Bang, Y. J. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Invest. New Drugs. 2011.
64. Feliu, J.; Borrega, P.; Leon, A.; Lopez-Gomez, L.; Lopez, M.; Castro, J.; Belda-Iniesta, C.; Barriuso, J.; Martinez, V.; Gonzalez-Baron, M. Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer Chemother. Pharmacol. 2011, 67 (1), 215-221.
65. Bao, P. Q.; Ramanathan, R. K.; Krasinkas, A.; Bahary, N.; Lembersky, B. C.; Bartlett, D. L.; Hughes, S. J.; Lee, K. K.; Moser, A. J.; Zeh, H. J., 3rd. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann. Surg. Oncol. 2011, 18 (4), 1122-1129.
66. Merchan, J. R.; Ferrell, A.; Macintyre, J.; Ciombor, K. K.; Levi, J.; Ribeiro, A.; Sleeman, D.; Flores, A.; Lopes, G.; Rocha-Lima, C. M. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Am. J. Clin. Oncol. 2011, (Epub ahead).